Pediatric Patients Demonstrate Progressive T1-Weighted Hyperintensity in the Dentate Nucleus following Multiple Doses of Gadolinium-Based Contrast Agent

References

1. 1.↵
   American College of Radiology. ACR Appropriateness Criteria. http://www.acr.org/Quality-Safety/Appropriateness-Criteria. Accessed March 14, 2016.
2. 2.↵
   2. Balassy C,
   3. Roberts D,
   4. Miller SF

   . Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies. Pediatr Radiol 2015;45:1831–41 doi:10.1007/s00247-015-3394-9 pmid:26045036

   CrossRefPubMed
3. 3.↵
   2. Ball WS Jr.,
   3. Nadel SN,
   4. Zimmerman RA, et al

   . Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 1993;186:769–74 doi:10.1148/radiology.186.3.8430186 pmid:8430186

   CrossRefPubMed
4. 4.↵
   2. Elster AD

   . Cranial MR imaging with Gd-DTPA in neonates and young infants: preliminary experience. Radiology 1990;176:225–30 doi:10.1148/radiology.176.1.2353096 pmid:2353096

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Hahn G,
   3. Sorge I,
   4. Gruhn B, et al

   . Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest Radiol 2009;44:776–83 doi:10.1097/RLI.0b013e3181bfe2d2 pmid:19858730

   CrossRefPubMed
6. 6.↵
   2. Lundby B,
   3. Gordon P,
   4. Hugo F

   . MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications. Eur J Radiol 1996;23:190–96 doi:10.1016/S0720-048X(96)01088-1 pmid:9003923

   CrossRefPubMed
7. 7.↵
   2. Schneider G,
   3. Schürholz H,
   4. Kirchin MA, et al

   . Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children. Pediatr Radiol 2013;43:202–11 doi:10.1007/s00247-012-2498-8 pmid:23179483

   CrossRefPubMed
8. 8.↵
   2. Dillman JR,
   3. Ellis JH,
   4. Cohan RH, et al

   . Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 2007;189:1533–38 doi:10.2214/AJR.07.2554 pmid:18029897

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Girardi M,
   3. Kay J,
   4. Elston DM, et al

   . Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011;65:1095–1106.e7 doi:10.1016/j.jaad.2010.08.041 pmid:21724294

   CrossRefPubMed
10. 10.↵
    1. Tschudy MM,
    2. Arcara KM

    2. Cooper S

    . Nephrology. In: Tschudy MM, Arcara KM, eds. The Harriet Land Handbook. 19th ed. Philadelphia: Elsevier Mosby; 2012:476–503
11. 11.↵
    2. Kanda T,
    3. Ishii K,
    4. Kawaguchi H, et al

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

    CrossRefPubMed
12. 12.↵
    2. Errante Y,
    3. Cirimele V,
    4. Mallio CA, et al

    . Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49:685–90 doi:10.1097/RLI.0000000000000072 pmid:24872007

    CrossRefPubMed
13. 13.↵
    2. Quattrocchi CC,
    3. Mallio CA,
    4. Errante Y, et al

    . Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015;50:470–72 doi:10.1097/RLI.0000000000000154 pmid:25756685

    CrossRefPubMed
14. 14.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905

    CrossRefPubMed
15. 15.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol 2015;50:805–10 doi:10.1097/RLI.0000000000000227 pmid:26523910

    CrossRefPubMed
16. 16.↵
    2. Weberling LD,
    3. Kieslich PJ,
    4. Kickingereder P, et al

    . Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 2015;50:743–48 doi:10.1097/RLI.0000000000000206 pmid:26352749

    CrossRefPubMed
17. 17.↵
    2. Kanda T,
    3. Fukusato T,
    4. Matsuda M, et al

    . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–32 doi:10.1148/radiol.2015142690 pmid:25942417

    CrossRefPubMed
18. 18.↵
    2. McDonald RJ,
    3. McDonald JS,
    4. Kallmes DF, et al

    . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

    CrossRefPubMed
19. 19.↵
    2. Roberts DR,
    3. Holden KR

    . Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of gadolinium contrast. Brain Dev 2016;38:331–36 doi:10.1016/j.braindev.2015.08.009 pmid:26345358

    CrossRefPubMed
20. 20.↵
    2. Miller JH,
    3. Hu HH,
    4. Pokorney A, et al

    . MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 2015;136:e1637–40 doi:10.1542/peds.2015-2222 pmid:26574593

    Abstract/FREE Full Text
21. 21.↵
    2. Kanda T,
    3. Osawa M,
    4. Oba H, et al

    . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803–09 doi:10.1148/radiol.14140364 pmid:25633504

    CrossRefPubMed
22. 22.↵
    2. Diedrichsen J,
    3. Balsters JH,
    4. Flavell J, et al

    . A probabilistic MR atlas of the human cerebellum. Neuroimage 2009;46:39–46 doi:10.1016/j.neuroimage.2009.01.045 pmid:19457380

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Diedrichsen J,
    3. Maderwald S,
    4. Küper M, et al

    . Imaging the deep cerebellar nuclei: a probabilistic atlas and normalization procedure. Neuroimage 2011;54:1786–94 doi:10.1016/j.neuroimage.2010.10.035 pmid:20965257

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Deoni SC,
    3. Catani M

    . Visualization of the deep cerebellar nuclei using quantitative T1 and rho magnetic resonance imaging at 3 Tesla. Neuroimage 2007;37:1260–66 doi:10.1016/j.neuroimage.2007.06.036 pmid:17702607

    CrossRefPubMed
25. 25.↵
    2. Fitzmaurice GM,
    3. Laird NM,
    4. Ware JH

    . Applied Longitudinal Analysis. Hoboken: Wiley-Interscience; 2004
26. 26.↵
    2. Gajjar A,
    3. Bowers DC,
    4. Karajannis MA, et al

    . Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol 2015;33:2986–98 doi:10.1200/JCO.2014.59.9217 pmid:26304884

    Abstract/FREE Full Text
27. 27.↵
    2. Murata N,
    3. Gonzalez-Cuyar LF,
    4. Murata K, et al

    . Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 2016;51:447–53 doi:10.1097/RLI.0000000000000252 pmid:26863577

    CrossRefPubMed
28. 28.↵
    2. Blakemore SJ

    . Imaging brain development: the adolescent brain. Neuroimage 2012;61:397–406 doi:10.1016/j.neuroimage.2011.11.080 pmid:22178817

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Stein J,
    3. Schettler T,
    4. Wallinga D, et al

    . In harm's way: toxic threats to child development. J Dev Behav Pediatr 2002;23:S13–22 doi:10.1097/00004703-200202001-00004 pmid:11875286

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Abraham JL,
    3. Thakral C

    . Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 2008;66:200–07 doi:10.1016/j.ejrad.2008.01.026 pmid:18374532

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Port M,
    3. Idée JM,
    4. Medina C, et al

    . Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008;21:469–90 doi:10.1007/s10534-008-9135-x pmid:18344005

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Robert P,
    3. Violas X,
    4. Grand S, et al

    . Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol 2016;51:73–82 doi:10.1097/RLI.0000000000000241 pmid:26606549

    CrossRefPubMed
33. 33.↵
    2. White GW,
    3. Gibby WA,
    4. Tweedle MF

    . Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272–78 doi:10.1097/01.rli.0000186569.32408.95 pmid:16481910

    CrossRefPubMedWeb of Science